{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-016083","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.097003+00:00","generated_at":"2026-06-26T04:14:41.830670+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TherapeuticsMD announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance","bullets":["Board approves 1-for-50 reverse stock split to cure Nasdaq minimum bid price non-compliance.","Effective May 6, 2022 at 5:00 p.m. ET; post-split trading on Nasdaq under \"TXMD\" begins May 9, 2022.","No stockholder vote required; fractional shares rounded up to nearest whole share.","Nasdaq granted extension to June 1, 2022 to regain compliance with $1.00 bid price.","Authorized shares reduced from 600 million to 12 million; authorized reduction matches split."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-016083","json":"https://secwatch.observer/filing/0001564590-22-016083.json","markdown":"https://secwatch.observer/filing/0001564590-22-016083.md","text":"https://secwatch.observer/filing/0001564590-22-016083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459022016083/0001564590-22-016083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459022016083/txmd-8k_20220427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:14:41.830670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}